Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients
-
Published:2018-04
Issue:4
Volume:29
Page:1037-1048
-
ISSN:0923-7534
-
Container-title:Annals of Oncology
-
language:en
-
Short-container-title:Annals of Oncology
Author:
Kim S.T.ORCID, Banks K.C., Pectasides E., Kim S.Y., Kim K., Lanman R.B., Talasaz A., An J., Choi M.G., Lee J.H., Sohn T.S., Bae J.M., Kim S., Park S.H., Park J.O., Park Y.S., Lim H.Y., Kim N.K.D., Park W., Lee H., Bass A.J., Kim K., Kang W.K., Lee J.
Subject
Oncology,Hematology
Reference20 articles.
1. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial;Bang;Lancet,2010 2. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: tyTAN–a randomized, phase III study;Satoh;JCO,2014 3. HER2 status in advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma for entry to the TRIO-013/LOGiC trial of lapatinib;Press;Mol Cancer Ther,2017 4. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: tRIO-013/LOGiC—a randomized phase III trial;Hecht;JCO,2016 5. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer;Kwak;N Engl J Med,2010
Cited by
85 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|